NEW YORK (GenomeWeb News) – Bioanalytical contract services firms Vitalea Sciences and Accium BioSciences today announced an agreement to cross-validate each other's' accelerator mass spectrometry platform.
The companies said successful completion of the studies "will permit delivery of bioanalytical services supported by backup AMS instrumentation operating under a unified and validated framework."
Financial and other terms of the deal were not disclosed.
AMS complements other tools for bioanalytical research and can be used to quantify the pharmacokinetics and metabolism of drug candidates prior to or as part of Phase 1 clinical trials.
Bob Bethem, CEO of Vitalea, based in Davis, Calif., said in a statement that his company and Accium will continue to compete for AMS studies, "but our labs share a common guiding principle to share our AMS services according to industry expectations. We will continue to provide the highest level of study design and execution at Vitalea with the added reassurance of this new backup contingency plan."
Ali Arjomand, president and COO of Seattle-based Accium, added, "The cooperative agreement announced here will bridge the AMS resources and technical expertise of both companies and provide greater value to pharmaceutical sponsors and the AMS community at large."